Apollomics Inc. (APLM)
NasdaqCM: APLM
· Precio en tiempo real · USD
17.06
-1.10 (-6.06%)
Al cierre: Aug 12, 2026, 3:30 PM
Apollomics Inc. (APLM) Stock Price, Analysis & Data
-6.06% (1D)
| Precio de compra | 17.6 |
| Capitalización de mercado | 37.46M |
| Ingresos (TTM) | 8.84M |
| Beneficio neto (TTM) | -10.94M |
| Beta | 1.45 |
| EPS (TTM) | -7.11 |
| Ratio PER (TTM) | n/a |
| Adelante PE | -26.25 |
| P/B (TTM) | -11.49 |
| P/S (TTM) | 4.24 |
| Earnings Date | n/a |
| Precio de venta | 18.46 |
| Volumen | 11,019 |
| Volumen medio (20D) | 24,316 |
| Abierto | 17.82 |
| Anterior Cerrar | 18.16 |
| Rango del día | 16.70 - 17.82 |
| Rango de 52 semanas | 3.66 - 42.12 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de APLM
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulati...
Industria Biotechnology
Sector Healthcare
IPO Fecha Nov 26, 2021
Empleados 14
Bolsa de Valores NasdaqCM
Símbolo bursátil APLM
Sitio web https://www.apollomicsinc.com
Desempeño financiero
En 2025, los ingresos de Apollomics fueron 8.5M, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -10.94M, una disminución de -79.69%.
Estados financieros